FDA's NDA And BLA Approvals: Kymriah, Vabomere, Cyltezo
Executive Summary
Original new drugs and biologics recently approved by US FDA.
You may also be interested in...
Top US FDA Official Says New 'Playbook' Needed For CMC Reviews Of Gene Therapy Products
CBER director says lack of a clear regulatory structure is holding back the development and acceleration of gene therapy products, while industry says regulations should be flexible to keep up with changing technology for these products.
Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access
US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.
Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model
Risk Evaluation and Mitigation Strategy for Kymriah requires the acute lymphoblastic leukemia treatment be administered by certified centers, while a postmarketing study will assess safety over 15 years. FDA's early approval reflects efforts by the biologics center and new cross-cutting Oncology Center for Excellence to implement a more collaborative review model.